drugset / Trial / NCT02962830

Sufentanil Pharmacokinetics After Intra Amniotic Injection

NCT02962830

Phase 2 Completed 8 enrolled University Hospital, Lille
NaSingle-groupOpen-labelTreatment

Summary

The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology (e.g., malformation) or a diagnostic or therapeutic procedure. To date, there is very little data and no consensus on fetal analgesia. The aim of the investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic injection.

Timeline

Start
2017-04-19
Primary completion
2024-05-28
Completion
2024-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 10 ug Other

Indications

No indication recorded.